The panel responsible for recommending which drugs England’s National Health Service (NHS) should prescribe may recommend against the organisation using cannabis-based medical products. The National Institute for Health and Care Excellence (NICE) has issued draft guidelines which say that in many cases, medical cannabis is both too expensive to be cost-effective and not well-researched enough to be recommended.
This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
LATEST ALERTS
